NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Bibliographic Details
Main Authors:	Jiejie Xu, Yu Zhu, Zewei Wang, Han Zeng, Zhaopei Liu, Yuan Chang, Yiwei Wang, Le Xu, Kaifeng Jin, Fei Shao, Sen Yan
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-05-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/5/e004569.full

Similar Items

POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1
by: Ge Liu, et al.
Published: (2024-02-01)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
by: Xuan Zhao, et al.
Published: (2022-08-01)

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
by: Elizabeth Ahern, et al.
Published: (2018-06-01)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
by: Youhai Jiang, et al.
Published: (2020-03-01)

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01)

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
by: Yuan Chen, et al.
Published: (2023-07-01)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
by: Bin Zhao, et al.
Published: (2020-07-01)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
by: Bogang Wu, et al.
Published: (2018-11-01)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
by: Yuedi Zhang, et al.
Published: (2022-06-01)

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
by: Xintong Li, et al.
Published: (2024-11-01)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
by: Meng Chen, et al.
Published: (2022-11-01)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
by: Tian Tian, et al.
Published: (2021-09-01)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.
by: Otgontuya Ganbaatar, et al.
Published: (2020-01-01)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
by: Laura Jimbu, et al.
Published: (2021-03-01)

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
by: Ali Razaghi, et al.
Published: (2023-08-01)

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
by: Oliver Kepp, et al.
Published: (2019-10-01)

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
by: Ming Yi, et al.
Published: (2022-01-01)

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
by: Inna Serganova, et al.
Published: (2017-03-01)

Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials
by: C. Bryce Johnson, et al.
Published: (2018-04-01)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
by: Daixi Ren, et al.
Published: (2020-01-01)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
by: Junyu Long, et al.
Published: (2017-08-01)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
by: Dawei Wu, et al.
Published: (2022-02-01)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
by: Rui Zhao, et al.
Published: (2021-01-01)

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
by: Menglei Jin, et al.
Published: (2024-11-01)

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
by: Jiawen Qian, et al.
Published: (2018-10-01)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
by: Daixi Ren, et al.
Published: (2020-02-01)

The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade
by: Yuchen Zhang, et al.
Published: (2024-11-01)

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
by: Weishi Cheng, et al.
Published: (2024-07-01)

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
by: Jun Gong, et al.
Published: (2018-06-01)

Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.
by: Stephen J P Blake, et al.
Published: (2015-01-01)

DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade
by: Gang Xue, et al.
Published: (2019-08-01)

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
by: Feifei Teng, et al.
Published: (2020-09-01)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
by: Mengjie Wang, et al.
Published: (2022-04-01)

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy
by: Xiaofan Su, et al.
Published: (2022-06-01)

Identification ACTA2 and KDR as key proteins for prognosis of PD‐1/PD‐L1 blockade therapy in melanoma
by: Yuchen Wang, et al.
Published: (2021-06-01)

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
by: Yilun Wu, et al.
Published: (2019-08-01)

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
by: Scott A. Tomlins, et al.
Published: (2023-02-01)